TIAP and Evotec Expand LAB150 BRIDGE Partnership to Include Amgen

Toronto Innovation Acceleration Partners (“TIAP”) and Evotec SE today announced that the two companies have expanded LAB150, their translational BRIDGE partnership, to include Amgen as a strategic partner. The expansion goes along with a combined investment of US$14M to expedite LAB150 programs towards the formation of new companies.

Read the full article

Previous
Previous

Feds, province announce funding for patient-oriented research in Ontario

Next
Next

Dementia in Canada: Cross-Country Report 2022